Hombach, J;
Friede, M;
Moorphy, V;
Costello, A;
Kieny, MP;
(2016)
Developing a vaccine against Zika.
BMJ-British Medical Journal
, 355
, Article i5923. 10.1136/bmj.i5923.
Preview |
Text
Hombach_Developing.pdf - Published Version Download (508kB) | Preview |
Abstract
The race to develop a vaccine against Zika began in February 2016, when the unusual clustering of cases of microcephaly and other neurological disorders associated with Zika virus infection led to the declaration of a public health emergency of international concern. When the World Health Organization held its first consultation in March, 14 active vaccine projects had already been announced.1 Today, WHO’s pipeline tracker counts about 30 active projects, pursued by developers from endemic and non-endemic countries, private and public sector.2 Such a jump start in vaccine development is rare, and several candidates have already progressed to clinical development. This pace is facilitated by our collective experience in developing vaccines against flaviviruses, the availability of novel vaccine technologies that greatly facilitate manufacturing of vaccines appropriate for trials in humans, and generous funding from some governments to support both basic research and product development.
| Type: | Article |
|---|---|
| Title: | Developing a vaccine against Zika |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1136/bmj.i5923 |
| Publisher version: | http://doi.org/10.1136/bmj.i5923 |
| Language: | English |
| Additional information: | This is an open access article distributed under the terms of the Creative Commons Attribution IGO License (https://creativecommons.org/licenses/by-nc/3.0/igo/), which permits use, distribution, and reproduction for non-commercial purposes in any medium, provided the original work is properly cited. |
| UCL classification: | UCL |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10056123 |
Archive Staff Only
 |
View Item |
